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Gerard A. Lutty, PhD; Christine Maric-Bilkan, PhD; Troy Stevens, PhD; H. Eser Tolunay, PhD; Walter Koroshetz, MD; on behalf of the “Small
Blood Vessels: Big Health Problems” Workshop Participants†
S mall blood vessels (generally <100 lm in internaldiameter) contribute to fundamental physiological pro-
cesses and pathological events, but may not necessarily
garner the attention associated with macrovascular physiol-
ogy and disease. Major reasons for the bench-to-bedside
research gap is the complexity and the size of small vessels
throughout the body. Small vessels contain diverse cellular
components and interact with a large variety of nonvascular
parenchymal cell populations that differ among various
organs. Depending on their location, the overlapping effect
of environmental, epigenetic, and developmental factors adds
to this complexity, challenging the translation of fundamental
discoveries to the bedside. A better understanding of the
speciﬁc structural and functional signatures of small vessels
throughout the body and how their local perturbations can
contribute to systemic pathophysiological conditions has the
potential to transform diagnostic and therapeutic approaches.
To advance this important area of science, the National
Institutes of Health held a workshop on September 18–19,
2014 that brought together scientists and clinicians from
diverse areas of microvascular research to share their latest
discoveries, identify common challenges, and foster
collaborative research on the physiology and pathology of
small blood vessels in many organs and tissues. The
workshop included 7 scientiﬁc sessions, entitled: (1) Basic
Biology and Natural History of Small Vessels; (2) Vascular
Dynamics; (3) Small Vessel Cellular Interactions; (4)
Transendothelial Transport, Including Across the Blood Brain
Barrier (BBB) in Health and Disease; (5) Small Vessels in
Disease; (6) Effects of Internal Milieu and Disease on Small
Vessels; and (7) Research Tools and Innovation. All sessions
and panel discussions are available in the National Institutes
of Health Videocast archive (http://videocast.nih.gov/PastE-
vents.asp). This white paper is not meant to be a compre-
hensive review of the topics. Rather it is meant to articulate
the gaps and opportunities identiﬁed by the workshop
participants. We regret any major omissions that might have
occurred. The top scientiﬁc priorities identiﬁed by participants
needing further study are summarized in Table.
Basic Biology and Natural History of Small
Vessels
The common structural component of all small blood and
lymphatic vessels throughout the body is the endothelium.
The endothelial layer is the only common cellular component
of capillaries, the simplest vascular structures with the
smallest diameter. While vascular smooth muscle cells
surround the endothelial layer in arterioles and venules,
outside the brain pericytes are quite abundant on small
venules and arterioles but are rather sparse on capillaries.1
Within the brain, however, there is controversy about pericyte
coverage of capillaries.2 Heterogeneity in endothelial cells is
particularly evident at the level of capillaries, where endothe-
lial cells speciﬁcally adapt to the needs of the surrounding
tissues.3 The endothelium varies in structural appearance in
different organs and may be continuous, discontinuous,
fenestrated, or sinusoidal in nature. Beyond controlling the
highly specialized blood–tissue exchanges needed for nutrient
transfer, signaling, or immune function, the endothelium
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performs other multiple key physiological functions, including
maintaining antithrombotic surface and in arterioles the
vasomotor tone.4 In fact, the endothelium can be viewed as
one organ, a giant mosaic whose parts follow patterns that
are shaped by environmental and developmental factors.5,6
Much remains to be learned about the mechanisms
involved in vascular development, including the bridge that
connects vascular development with endothelium specializa-
tion; the molecular and physical factors that determine the
precise temporal arrangement, shape, branching, and size of
the vasculature; and the elements that modulate endothelial
barrier function (Figure 1).7 This session identiﬁed the need
for interdisciplinary teams to help decode the entire normal
and pathological tissue-speciﬁc molecular heterogeneity pat-
terns of the endothelium. This knowledge is needed to
develop better prognostic and diagnostic markers for a variety
of local and systemic diseases, and might one day allow the
precise tissue targeting of new therapies by delivery to the
correct “endothelial ZIP-code.”8
The function of the endothelial lining involves signiﬁcant
“cross-talk” within the vessel wall, between the endothelial
and mural vascular cells, and between bloodborne cells and
signals, small vessels, and their surrounding tissues. Integra-
tion of the vascular structure and function across spatial and
temporal scales, from genes to tissue, is key to understanding
vascular development and physiological and pathological
remodeling. Angiogenesis, arteriogenesis, the growth of
collateral vessels, and the regression of vascular structures
are dynamic events that can occur over a relatively short time
span. These remodeling phenomena may affect an individual’s
propensity to adverse events such as myocardial infarction
and stroke, and their manifest severity, and are inﬂuenced by
individual genetic and environmental factors.9,10 Different
strains of mice exhibit differences in arteriogenesis, depend-
ing on the location of preexisting connections between
arterioles, as well as differences in their susceptibility to
disease,11 supporting the role of genetics in vascular remod-
eling. For instance, the density of brain collateral circulation is
strongly determined by genetic background and is an
important determinant of stroke outcome in animals and
potentially humans.12,13
Similarly, facets of the lymphatic system that can inﬂuence
inﬂammation and the vascular response to disease are also
genetically determined.14 It is less clear, however, what
particular genes specify variation in the formation, mainte-
nance, and remodeling of small vessels. Furthermore, there is
a paucity of information about how genetic variants inﬂuence
the response of small vessels across the lifespan. Some
genetic susceptibility factors seem to be shared across
different manifestations of small vessel disease.15
Recent data indicate that pericytes can control microvas-
cular remodeling and angiogenic switching.16 “Angiophagy,”
leading to the loss of vascular structures (also recognized in
aging), also emerged as potentially critical for vascular
occlusion and recanalization.17–19 It is recognized by this
session that new computational approaches that could
integrate all factors that affect vascular development and
remodeling to simulate these processes using stochastic or
deterministic rules could greatly advance the ability to predict
individual risk and possibly prevent disease.
Sex is a critical biological determinant that modulates
microvascular pathophysiology.20 The relative concentration
Table. Top Scientiﬁc Priorities From the National Institutes of Health (NIH) Workshop “Small Blood Vessels: Big Health Problems?”
Basic biology and natural history of small vessels Understand the mechanisms driving complex local specialization of endothelial cells and development of
small vessels, in order to identify therapeutic targets that take into account the heterogeneity in
structure and function of the endothelium between distinct organs and within a tissue and the influence
of genetic determinants, sex, hormonal status, and age
Vascular dynamics Visualize with spatial and temporal fidelity the critical subcellular signal transduction networks,
intermolecular interactions (eg, molecular anatomy), and cell–cell and cell–matrix properties in health
and disease
Small vessel cellular interactions Understand the molecular and cellular processes in homeostasis and response to injuries of small
vessels, and how cellular and organ-specific environments influence this response
Transendothelial transport, including blood–brain
barrier, in health and disease
Deconstruct the regulation and function of the neurovascular unit (including adhesion, extracellular
matrix, tight and adherens junctions and transcytosis) in health, and reconstruct them in disease
Small vessels in disease Develop translational, mechanism-based therapies to prevent or slow progression of small vessel
diseases and define which patients to treat, and when and how to treat them
Effects of internal milieu and disease on small
vessels
Develop better and clinically relevant models of diseases of small vessels and elucidate the interactions
between vasculature, inflammation, and immune activation across the lifespan
Research tools and innovation Develop and integrate synergistic biological, technological, and computational advances in order to
understand complex, dynamic interactions among different signaling pathways, cell types, cells and
matrix proteins, small and large vessels, and vessels and their microenvironments, through
multidisciplinary teams
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of sex hormones that exist both in males and females varies,
which means the sex biological biasing factors vary across the
lifespan.21 Sex differences occur in incidence and presenta-
tion of cardiovascular disease, chronic kidney disease, and
vascular dementia.22–24 Preeclampsia, menopause, and erec-
tile dysfunction are sex-speciﬁc conditions reﬂexing the
complement of sex chromosomes and sex hormones,25 and
are associated with small blood vessel dysfunction, but we
still do not understand these associations at a fundamental
level. Hormonal variation affects expression of genes, and
mosaicism of X inactivation in females may not be as random
as previously thought. Interestingly, changes in small vessel
structure (such as remodeling) and function can be markedly
different in males and females, or in response to sex
hormones. For example, ﬂuctuating levels of sex hormones
have important consequences on stroke outcome in female
animals, and marked changes in the endothelial lining of small
blood vessels appear during pathologies associated with
pregnancy such as preeclampsia and eclampsia.26–30 In the
peripheral microcirculation, endothelin-mediated vasocon-
striction or nitric oxide–mediated endothelium-dependent
vasodilation is signiﬁcantly affected by sex steroids and may
underlie pathology in polycystic ovary syndrome.31 Therefore,
careful attention should be given to sex and reproductive
history in experimental design for both preclinical and clinical
research. An integrative approach is needed to discover how
sex affects vascular function within all components of the
circulatory system.
To advance the understanding of small vessel disease,
cross-disciplinary research and the development of new tools
that include computational modeling and imaging could
enable integration of data across scales, ranging from
molecular to tissue levels. Additionally, the ﬁeld needs to
better understand the mechanisms driving complex local
structural and functional specialization of endothelial cells and
how blood vessels develop and remodel across the lifespan. A
better deﬁnition of “small vessel disease” that can affect the
brain, heart, kidney, or other organs, as well as an integrative
Figure 1. Differences in the functional small blood vessel architecture and normal perfusion of various
mouse organs. Systemically injected ﬂuorescent microspheres are tightly contained with the vascular
structures with continuous endothelium, exempliﬁed in skeletal muscle and brain by the smooth
appearance of the small vessels. In contrast, microspheres cross through the fenestrated endothelium of
kidney glomeruli and escape through the pores of the discontinuous endothelium of spleen sinusoids
(Zorina Galis, unpublished data).
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approach to discerning causation of small vessel disease are
needed to identify new diagnostics and therapeutic targets
and biomarkers.
Vascular Dynamics
The vascular tone (resistance) is regulated to match blood
ﬂow to metabolic demand in order to provide adequate
profusion to tissues under different physiological conditions.
As an example, afferent and efferent arteriole resistances are
differentially controlled to regulate ﬁltration dynamics in the
glomerular capillaries that lie in between these portal
resistance elements. Mechanical forces are stimuli that
mediate these regulatory effects. Mechanosensation of blood
pressure and ﬂow contributes to vasculogenesis and vascular
remodeling. Alterations in transduction of the mechanical
signal, ie, mechanotransduction, are associated with disease
processes such as hypertension, diabetes, atherosclerosis,
and large vessel stiffening. Although many putative mechan-
otransducers have been identiﬁed,32 much work remains to
be done to understand in detail how these various compo-
nents orchestrate responses to shear stress.
Many challenges remain for understanding vascular
dynamics. At the macro-scale, it is important to identify
speciﬁc sensors in endothelial and vascular smooth muscle
cells, their biochemical and cellular signaling pathways in
different organs, and their synergy with systemic risk factors
in disease progression. At the meso-scale, work is needed to
characterize microvascular cellular topology in relationship to
organ function. At the micro-scale, it is important to elucidate
how single cell function within small blood vessels themselves
inﬂuences the vasculature. These goals can be achieved
through a better understanding of microanatomy and micro-
physiology, genomics, proteomics, and metabolomics
throughout the circulatory system. Opportunities for scientiﬁc
advances include elucidating the heterogeneity of cellular
phenotypes; understanding the mechanics and development
of the matrix, and the long-range interactions (mechanical,
electrochemical, and bloodborne); developing cell-free scaf-
folds to be used for tissue engineering; imaging in 3
dimensions with high temporal and spatial resolution; and
mathematical modeling to integrate these concepts with real
vascular dimensions, functions, and biochemical processes.
Several gaps remain in our understanding of the role of the
microcirculation in important fundamental mechanisms in
health and in disease, such as metabolic hyperemia and the
etiology of small vessel disease (SVD). For example, much
remains to be understood regarding the causal relationship
between coronary microvascular disease and ischemic heart
disease. New methods for high-resolution ex vivo imaging and
morphometry of the entire coronary vasculature in pigs, other
large mammals,33and mice34 will help ﬁll these gaps.
However, technological advances, such as biosensors for
understanding intracellular and macro-scale signaling and
mechanics; higher resolution and speed, imaging technologies
that can penetrate into deeper layers of tissues in vivo,
including intrinsic ﬂuorescence; fate mapping for disease
etiology, eg, site for angiogenesis; and new transgenic and
conditional animal models are needed to further advance the
ﬁeld.
Small Blood Vessel Cellular Interactions
Although the microvasculature shares common structural and
functional characteristics in many organs, there are also
important organ-speciﬁc features. Endothelial cells of small
vessels closely interact with smooth muscle cells, pericytes,
and tissue-speciﬁc nonvascular cells, as well as circulating or
tissue resident immune cells. Vascular smooth muscle cells
interact and communicate with endothelial cells in the control
of vascular tone. Nonvascular and vascular interactions shape
the physiological responses and pathophysiological outcomes
following injury and in microvascular complications.7 These
interactions are in turn inﬂuenced by microenvironment and
organ-speciﬁc drivers.35 For instance, antibody-mediated
inﬂammation and injury of glomerular capillaries, which carry
out the ﬁrst step of ﬁltering blood, underlie many glomerular
disorders in the kidney.36
The immune system changes with aging toward a more
aggressively pro-inﬂammatory state. Alterations in the adap-
tive and innate immune system contribute to age-associated
morbidity and mortality, and increased pro-inﬂammatory
cytokines (eg, interleukin-6, tumor necrosis factor-a) in aging
have been associated with hypertension, atherosclerosis,
dementia, and diabetes, among other diseases. However,
there is a strict territorial behavior of inﬂammatory disease,
and aging is not always the cause. Elucidating the role of
inﬂammation on vascular health and disease constitutes an
important scientiﬁc gap.
Many features of the immune interactions with small blood
vessels remain poorly understood. These immune interactions
include target organ susceptibility factors that dictate the
extent of the immune response and damage initiated by
deposited antibodies37; differences in the characteristics of
immune responses following deposition of soluble immune
complex versus in situ immune complex formation; and the
mechanisms by which neutrophils and their cross-talk with
other immune cells induce injury. For example, in the kidney,
work is needed to understand how immune cells contribute to
chronic glomerulonephritis; how glomerular inﬂammation
leads to tubulo-interstitial damage, which predicts the pro-
gression to end-stage renal disease; and, how microvascular
DOI: 10.1161/JAHA.116.004389 Journal of the American Heart Association 4
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inﬂammation increases the risk for macrovascular disease (eg,
atherosclerosis). Some similarities between the pathology of
small blood vessel disease in the kidney and the brain suggest
that similar mechanisms may be at work.
Excessive oxidative stress of cells of the vascular wall
resulting from altered metabolism, inﬂammatory cytokines, or
mechanical forces contributes to vascular diseases. However,
large clinical trials in which antioxidants have been given in
high-risk patients for the prevention of cardiovascular events
did not demonstrate the expected beneﬁts,38–40 in part
because redox-responsive pathways that induce speciﬁc
organ pathology have remained elusive. Obstacles to deci-
phering speciﬁc redox-dependent pathways are the localized
nature of reactive oxygen species (ROS) production (eg, in
caveolae, lipid rafts, endosomes, or mitochondria), the
particular properties of the oxidants (eg, superoxide, perox-
ynitrite), and the plethora of chemical protein modiﬁcations
(eg, sulfenylation, glutathionylation) and their reversible
nature.41 New technologies to resolve intracellular reactive
oxygen species spatially and temporally, integrated in silico
algorithms to predict redox modiﬁcations, and reliable
methods to identify redox modiﬁcations by mass spec-
troscopy would facilitate progress in understanding vascular
oxidative stress. Additionally, redox signaling occurs in
parallel to other key signaling events, eg, calcium- and
reactive oxygen species–dependent signaling pathways,
which can interact and modulate the activity of each other.42
An integrated approach is required to determine the physi-
ological relevance of speciﬁc vascular redox pathways and
their interplay with other key processes in the adjacent cells
and within tissues.
Ex vivo vascular modeling systems could provide the
opportunity to study disease mechanisms. Such systems have
been used to investigate thrombosis, in particular, self-
assembly of von Willebrand factor, endothelial barrier func-
tion, angiogenesis, and diseases affecting small vessels
including thrombotic microangiopathies (including thrombotic
thrombocytopenic purpura), sepsis, malaria, and sickle cell
disease.43 These systems allow the effect of changes in
different physiological or pathological parameters, such as
shear stress, ﬂow rates, vessel geometry, and role of other
cell types to be studied in real-time. However, the systems
need to be improved to overcome low throughput and
developed to apply to the central nervous system (CNS) and
other organs.
Transendothelial Transport, Including Across
the BBB, in Health and Disease
The major microvascular barriers of the brain, the blood–brain
barrier (BBB) and the blood–cerebrospinal ﬂuid barrier, and of
peripheral nerves, the blood–nerve barrier (BNB), share unique
properties required to tightly regulate the transport of ions,
solutes, nutrients, and macromolecules between the periph-
eral circulation and the neural parenchyma, as well as control
hematogenous leukocyte trafﬁcking during physiologic and
pathophysiologic conditions. The BBB is a very restrictive
layer of highly specialized endothelial cells that exist
throughout the brain vessels, and is even more specialized
in capillaries and the inner layers of postcapillary venules in
the brain (Figure 2A). In the brain, processes from neighbor-
ing astrocytes and microglial cells contribute to the BBB,
forming the neurovascular unit (Figure 2B). These cells can
regulate barrier function, contributing to the internal home-
ostasis of the brain as required for signal transduction. Blood
cells, particularly polymorphonuclear cells, lymphocytes, and
monocytes, also interact with the endothelium and may affect
the neurovascular unit.44 Similarly, the BNB is formed by
specialized endothelial cells that form microvessels within the
innermost layer of peripheral nerves and nerve roots (the
endoneurium).45 These endothelial cells exhibit highly
restricted pinocytosis and transcytosis potential, express
speciﬁc transporters that regulate the inﬂux/efﬂux of nutri-
tive/toxic compounds, express low levels of leukocyte
adhesion molecules under normal physiologic states and an
array of specialized proteins that form tight and adherens
intercellular junctions that efﬁciently restrict passive diffusion
of bloodborne molecules and contribute to a high
transendothelial electrical resistance (Figure 3A). In addition,
extracellular matrix adhesion of endothelial cells by integrins
can determine tight junction ﬁdelity.46 These specialized
endothelial cells are surrounded by pericytes that share a
common basement membrane.
Altered BBB permeability has been implicated in small
vessel disease, lacunar stroke, vascular dementia, and
Alzheimer’s disease.47 Alternations in BNB structure, such
as basement membrane thickening (Figure 3B), have been
described in chronic peripheral nerve disorders such as
diabetic neuropathy and chronic inﬂammatory demyelinating
polyneuropathy.48
A special paravascular space described in the rodent brain
serves as a lymphatic system in the CNS.49 This highly
polarized macroscopic ﬂuid transport system has been
termed the “glymphatic” system. Aging and microinfarcts
appear to be linked to a marked reduction in glymphatic
activity. Alzheimer’s disease is also thought to be a conse-
quence of altered perivascular drainage due to faulty removal
of b-amyloid from the brain by the glymphatic transport and
accumulation of b-amyloid proteins. The effects of changes in
BBB permeability, hypertension, diabetes, SVD, and other
comorbidities on glymphatic clearance, as well as the role of
individual cell types in the neurovascular unit on glymphatic
activity, are unknown. More importantly, the presence of the
glymphatic system in the human brain remains to be
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Small Blood Vessels: Big Health Problems? Bosetti et al
S
P
E
C
IA
L
R
E
P
O
R
T
demonstrated, which requires development of human
biomarkers of glymphatic activity.
Cerebral SVD can be sporadic or hereditary, and is
characterized by leakage of plasma proteins into the vessel
walls and perivascular spaces. SVD is thought to play a role in
the pathogenesis of neurodegenerative diseases including
Alzheimer’s disease, dementia, and cognitive decline, retinal
vasculopathy with cerebral leukodystrophy, white matter
disease, and lacunes of the central gray matter. The
processes initiating SVD of the CNS are not exactly known
but may involve hypoxia/ischemia, inﬂammation, pericyte
degeneration, and alteration in BBB capillary function, result-
ing in BBB leakage. Improvements in neuroimaging and
studies in animal models are needed to address gaps in
knowledge of the etiology, risk factors, or triggers of SVD.
Transcellular transport is another dynamic process that
needs to be further elucidated. Depending on the tissue or the
disease state, the passage of a macromolecule from periph-
eral circulation into the CNS or peripheral nerves could be the
result of increased paracellular entry attributable to alter-
ations in intercellular tight junction function or an active
transport process (eg, receptor- or caveolae-mediated tran-
scytosis). Advancing knowledge of the repertoire of
transporters and their function, expression, and regulation
would help improve small molecule drug delivery into the
brain and peripheral nerves, and in turn, treatment of
neurological and psychiatric disorders.
Additional gaps in knowledge and areas for future research
include a better understanding of junctional formation and
disassembly of the BBB and BNB, such as signaling pathways
that reassemble both adherens and tight junctions to restore
endothelial barrier; the precise workings of endothelial
transcytosis pathways and transcellular pores and means of
exploiting them to deliver polar or large drugs across
restrictive barriers; mechanisms by which the endothelial
barrier coordinates the passage of ﬂuid and solutes as well as
circulating hematogenous and neoplastic cells; reasons
underlying the incapacity of some microvascular barrier
systems to adequately repair; and the restoration of endothe-
lial integrity. We also need to identify differences among
developmental/reparative angiogenesis, collaterogenesis, and
pathological neovascularization, develop therapeutic interven-
tions to promote vascular repair, and better understand the
role and interactions of cellular and humoral factors in
microvascular barrier formation and adaptation, in health and
disease.
EC
PVM
Cerebral 
arteriole
PERIVASCULAR SPACE Glia limitans
A B
Figure 2. A, The neurovascular unit at the level of a pial arteriole (Courtesy of Dr Giuseppe Faraco, Weill
Cornell Medical College). B, Perivascular microglial cells. This deconvolution ﬂuorescence microscopy
image illustrates the proximity of microglial cells to a cerebral capillary in the adult rat hindbrain. A 30-lm
frozen rat brain section was stained for Iba1 (red), a microglial marker, and MHC II (green), which is
upregulated in activated microglia but also stains endothelial cells. Nuclei were stained with 40,6-diamidino-
2-phenylindole (DAPI) (blue). Microglia are the resident macrophage of the CNS and serve a number of roles
including defense against pathogens that cross the BBB. Note the difference between the “surveillance
state” microglia (white arrow), which has a small amount of punctate green MHCII staining on the processes
and the “activated” microglia (yellow arrow), which has increased punctate MHCII staining that deﬁnes the
outline of the processes. The capillary, indicated by the green MHCII staining, winds between the 2
microglial cells. This image is a maximum intensity projection of a 10-lm-thick segment of the brain slice.
BBB indicates blood–brain barrier; CNS, central nervous system; EC, endothelial cell; PVM, perivascular
macrophage; SMC, smooth muscle cell.
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Small Vessels in Disease
Microvascular complications are well-recognized effects of
longstanding hypertension or diabetes.50 In addition, small
blood vessels themselves cause or contribute to a diversity of
diseases and pathogenic processes, such as hypertension,
coronary microvascular disease, pulmonary hypertension,
sepsis, focal strokes, microinfarcts, large cerebral hemor-
rhages or microscopic hemorrhages (microbleeds), and
dementia.26 Additionally, subtle and chronic changes in
vascular structure and function can lead to cerebral white
matter damage and cognitive dysfunction. These are accom-
panied by increased BBB permeability, endothelial dysfunc-
tion, and alterations in myogenic tone, neurovascular
coupling, and consequently cerebrovascular autoregulation.27
Hypertension is a risk factor for Alzheimer’s disease and
increases in blood pressure are linearly related to a decrease
in cognitive abilities.28 Deleterious microvessel changes, such
as those underlying chronic hypertension, can occur very
early and exacerbate other pathological processes in many
tissues and organs.51 For instance, diabetes superimposed on
hypertension exacerbates small artery remodeling and the
degree of remodeling is greater in diabetics than in nondia-
betic hypertensive patients.52,53 In the kidney, glomerular
injury leading to renal insufﬁciency can arise from hyperten-
sion, impairment of microvascular function, inﬂammatory
insult, or autoimmune conditions.36,54 Over prolonged peri-
ods, the impairment in vascular regulation in the kidney could
accelerate progression of renal injury, and in the brain it could
lead to cognitive impairment via chronic mismatch between
the delivery of nutrients through blood ﬂow and the brain high
energy requirements, particularly in the subcortical white
matter.24
Large cerebral arteries, pial arterioles, intraparenchymal
arterioles, capillaries, and venules react in a dramatically
different way to hypertension. Stiffening, atherosclerosis,
remodeling, collagenosis, and lipohyalinosis are observed in
different vascular districts, resulting in distinct pathologies.
For example, in the presence of atherosclerosis, the coronary
endothelial vasomotor response to acetylcholine is frequently
reduced but is variable between patients,55 and in the CNS
large vessel atherosclerosis may lead to vascular occlusion
and focal stroke, small vessel atherosclerosis to microin-
farcts, lipohyalinosis to white matter disease, and venous
collagenosis may promote hemorrhage or microbleeds.26
However, it remains to be established how different vascular
segments of the cerebral microcirculation react to, or
contribute to the etiology of essential hypertension and what
the underlying mechanisms are. Therefore, it is important to
investigate the effect of hypertension and other risk factors
on different segments of the circulation and identify relevant
cellular and molecular mechanisms leading to vascular
dysfunction and damage, particularly at the level of small
vessels.
One major challenge that lies ahead is to develop
translational, mechanism-based therapies to prevent, or slow,
progression of small vessel disorders. The key components of
this intervention are deﬁning who, when, and how to treat.
A B
Figure 3. A, Tight junctions at the human blood–nerve barrier (BNB). A digital electron micrograph of the
BNB in the sural nerve from an untreated adult patient with Guillain-Barre syndrome shows intact electron-
dense intercellular tight junctions (white arrows). Scale bar=0.5 lm. B, Human BNB alterations in disease.
A digital electron micrograph of the BNB in the sural nerve from an adult patient with chronic inﬂammatory
demyelinating polyneuropathy shows BM thickening/duplication between endoneurial EC and pericytes (P).
Intact electron-dense intercellular tight junctions (white arrows) are seen. Perivascular T-lymphocytes (TL), a
common feature in immune-mediated polyneuropathies, are also observed. Scale bar=5 lm. BM indicates
basement membrane; EC, endothelial cell; L, lumen; P, pericyte; RBC, red blood cell.
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Accurate assessment of vascular health is complicated
because microvessels are small, and within the tissue
parenchyma, relatively inaccessible to observation without
invasive biopsy, with few exceptions (eg, retina).
Finding treatments for vascular cognitive impairment has
been impeded by patient heterogeneity and lack of biomark-
ers of key microvascular processes related to cognitive and
neurologic impairment. Identifying homogeneous subgroups
of vascular cognitive impairment patients (eg, Binswanger’s
disease) by multimodal biomarkers-based clinical examina-
tion, magnetic resonance imaging studies of BBB permeability
and microstructure, and cerebrospinal ﬂuid studies indicative
of inﬂammation, which indicates pathophysiology of white
matter injury, would accelerate development of effective
treatments.56 Still needed are validations of a biomarker
approach in larger populations, identiﬁcation of outcome
measures, and development of drugs to test in treatment
trials.
Achieving rapid, robust, and noninvasive assessment of
vascular health with sufﬁcient resolution is a major challenge,
especially for microvessels. Technological advances to
develop noninvasive monitoring and improve imaging tech-
niques to longitudinally visualize small vessels without biopsy
will allow early detection and monitoring of disease progres-
sion and provide a greater appreciation for the natural history
of SVDs.
Clinical and preclinical studies to identify sensitive and
accurate circulating (and nonvascular) biomarkers as surro-
gate readouts of vascular health will represent critical
advances. Development of methods for rapid, robust, and
noninvasive sampling of vascular health will allow early
detection, early intervention, and better assessment of
disease progression in patients. Earlier detection may lead
to identiﬁcation of underlying contributing factors, including
potentially modiﬁable risk factors that do not require thera-
peutic interventions. Identifying the earliest signs of disease
by advanced imaging or circulating biomarkers will also deﬁne
a therapeutic window, and guide the selection of patients to
treat and the time of treatment. The ability to noninvasively
monitor disease progression, stability, or regression can
inform modiﬁcations to patient care. Importantly, accurate
and robust methods to quantify these parameters will improve
the ability to critically assess early success or failure of
potential therapies in clinical trials. As methods for advanced
detection become easier, faster, and cheaper, they may be
adopted as accepted surveys of vascular health, resulting in a
greater number of patients being tested. This will translate
into more powerful disease-prevention efforts and improved
vascular health.
Genetic investigations will continue to be important in
deﬁning, identifying, and treating those patients who are at
greatest risk of vascular disease. With increasing cohort sizes
in highly powered genomewide-association studies that are
dichotomized by sex and the increasing availability of
personalized data through genome or exome sequencing,
the breadth and depth of understanding of genetic risk factors
are increasing at unprecedented rates. The availability of
individual genetic data will reﬁne both general and personal
genetic risk factors, which could be used to prioritize patients
who should be closely monitored. For example, polymor-
phisms in novel genes that are responsible for variation in the
extent of the native collateral circulation in brain and other
tissues, as well as collateral remodeling in models of occlusive
disease, recently have been identiﬁed in mice and are being
investigated for similar impact in humans.12,57,58 Early
identiﬁcation and intervention for individuals at greatest
genetic risk can allow prevention of microvascular diseases,
or tributary insults, rather than treating patients long after
disease has begun. Complex, multifactorial diseases are
unlikely to have “magic bullet” therapies and will instead
require treatment of mechanistically related subsets of
patients. Greater deﬁnition of the genetic landscape and
architecture for vascular disease will allow identiﬁcation of
individual signatures to genetically stratify clinical drug trials,
which may avoid unnecessarily rejecting drugs that may be
efﬁcacious in subsets of patients or to better predict
individual drug responses.
A critical step is the development and use of disease-
relevant animal models to understand the primary molecular
mechanisms and to de-convolute biological complexities
arising from interactions between multiple processes (oxida-
tive stress, inﬂammation, extracellular matrix) that can differ
with sex, age, comorbidities, etc. The use of combinations of
risk alleles and inbred strains of mice allows tight control and
simpliﬁcation of genetic factors that contribute to disease,
making these complex interactions approachable. On the
other hand, outbred animal strains and recently developed
mouse genetic mapping populations are also useful to
understand population responses and provide genetic diver-
sity that may be more suitable for evaluating population
results in preclinical models.59 Development and character-
ization of disease-relevant animal models through hypothesis-
driven gene targeting or validations of human loci will be
invaluable to understanding cellular pathways and preclinical
testing of novel therapeutics. For example, CRISPR method-
ology has enabled construction of mouse lines with poor,
intermediate, and abundant collaterals in brain and other
tissue by mutation of a single base-pair in an otherwise
isogenic background, thus providing a model of variation in
collateral circulation that is evident in humans.57 Collabora-
tive investigations merging concepts from human studies
with those from basic cellular and animal models are viewed
as the best approach to hasten translation to improved
patient care.
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Effects of Internal Milieu and Disease on
Small Vessels
Small vessels respond to local signals and hemodynamic
forces differently depending on their structure, location,
microenvironmental and systemic milieu, and/or the pres-
ence or absence of disease. While prolonged changes in local
internal environmental conditions, including hemodynamic,
bloodborne, and local tissue-derived stimuli, can lead to
compensatory or pathological changes in the small vessels of
the body, genetic contributions should also be considered.
It has become clear that small vessels are dynamic and can
exhibit plasticity. Examples include pharmacological control of
diabetes or hypertension, which can reduce damage to small
vessels and pathologic formation of new vessels and restore
normal function.60,61
In diseases such as diabetes and stroke and in premature
births, remodeling may include angiogenic responses result-
ing in newly formed vessels that may not be functional, and
may serve only to exacerbate inﬂammatory processes within
the body.28,30 During hypertension, small vessel inward
remodeling to generate smaller lumens and thicker walls
can be protective of vascular injury by increasing vascular
resistance and preventing high perfusion pressures from
damaging downstream capillaries.62 However, smaller lumen
diameters can produce chronic hypoperfusion and infarction,
and can limit vasodilator reserve in an organ as well as
increase total peripheral resistance, which contributes to the
hypertension.63 While this response to hypertension has been
known for decades, how it differs in males and females, in
response to hormonal status, or the inﬂuence of genetics is
not known. In addition, how small blood vessels respond
differentially to disease in different organs is largely unknown.
An important example is preeclampsia, which affects the
small vessels of many organs including the kidney, placenta,
brain, and heart.10 How the small vessels of each organ are
affected during preeclampsia may be signiﬁcantly different yet
important to understand for effective treatment and preven-
tion of this condition.
Research Tools and Innovation
Complex interactions among cell types inﬂuence both the
micro- and macroenvironments of the vasculature. Overlap-
ping processes that may be deleterious in an acute phase of
disease or injury may be adaptive and beneﬁcial during
healing and repair. Thus, it is important to consider that
responses to disease and injury may be time- and cell-type
dependent, as well as organ speciﬁc. To study them, there is a
continuing need for advances in technologies for systematic
measurement, including imaging, genomics, proteomics,
bioinformatics, and similarly in mathematical and
computational models to describe and predict complex
dynamic behaviors.64
Model systems have played an important role in elucidat-
ing mechanisms of pathology and disease, and in the
development of therapeutic interventions. Recent advances
in bioengineering, stem cell technology, and microscopy have
led to emergence of model systems that will accelerate
scientiﬁc discovery and translation.65 Techniques such as 2-
photon microscopy and optogenetics2 provide new insights
into the physiology and pathology of vascular disease in
animal models. In vitro models are being developed that
utilize tissue engineering and stem cell technology to
recapitulate the vascular microenvironment of different
organs with human cell lines. Computational models have
been important in understanding circulation at macroscopic
length scales, and advances in computational power are
enabling the development of models at the cellular and
molecular level. These emerging models are capable of
simulating membrane dynamics, receptor/ligand interactions,
transcellular transport processes, and in the near future will
be capable of simulating vessel growth and remodeling.66
Currently, heterogeneous groups of disease processes are
often lumped into single diagnoses (eg, vascular cognitive
impairment or hypertension). Moreover, some disease pro-
cesses are thought to be due primarily to large vessel disease,
while others are attributed to small vessel disease. There is a
strong need to better delineate the subtleties of disease and
interactions among large and small vessels as well as among
different vascular regions (eg, extracranial and intracranial, or
aortic and renal).67
Integrative, multidisciplinary approaches are needed to
improve tools for visualization and analysis suitable for
understanding systems biology and pathophysiology across
scales, in both animal models and individual patients, and for
informing and validating much-needed integrative, multiscale
computational models. For example, there is a need for better
information on 3D structure, function, and hemodynamic
conditions in small-to-large vessels in different, yet intercon-
nected, vascular beds,68–70 as well as for better validation of
both the integrity of the data and the reliability of the methods
used to analyze or simulate them.
The ﬁeld should leverage emerging tools to improve our
basic understanding of microvascular function in health so
that we can delineate alterations in disease, including the
development of high-throughput metabolomic screens; map-
ping epigenetic changes in health and disease; and a better
understanding of the role of the microenvironment on
microvessels in different tissues.
Emerging data suggest that the small vessel “vasculome,”
deﬁned as the integration of RNA expression, epigenetic,
protein, and metabolomic proﬁles, is organ speciﬁc and may
contribute to disease pathophysiology and biomarker
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generation.71 Mapping the functional “vasculome” in different
organs, and having an integrated vasculome database for all
major target organs could provide a unique resource/tool for
pursuing therapeutic and diagnostic leads in disorders of the
small vessels. Possible differences due to sex, race, and age,
which could impact drug delivery, drug penetration, uptake,
and therapeutic outcome, also remain largely understudied.
Finally, the ﬁeld needs to create better opportunities for the
exchange of ideas and data, particularly across disciplines,
from basic scientists and engineers to clinicians. To achieve
this, precise terminology, standardization, and sharing of data
acquisition and analysis technologies as well as interdisci-
plinary collaborations are needed.
Summary and Future Directions
The workshop provided a ﬁrst-time opportunity for scientists
from different disciplines to come together and identify
common challenges and scientiﬁc opportunities for basic and
clinical research on small blood and lymphatic vessels. Among
the cross-cutting priorities, participants identiﬁed the need to
expand our knowledge of the basic biology of small vessels;
the structural and functional heterogeneity and differential
susceptibility to injury and disease; the interactions of
vascular cells with their neighboring cells and circulating
factors; the molecular mechanisms of physiological and
pathological autoregulation of small vessels in different
organs; and the tissue-speciﬁc phenotypes of endothelial
cells, pericytes, or vascular smooth muscle cells that
contribute to different vessel dynamic responses. An appre-
ciation of factors, such as sex, hormonal status, developmen-
tal stage, age, comorbidities, and genetics are critical for
understanding the complexity of the physiological and patho-
logical responses of small blood vessels. Novel integrated
multidisciplinary approaches to address computational mod-
eling, noninvasive imaging, genetic determinants, and devel-
opment of new animal models are key to address the
pathophysiology of small blood vessels.
A challenge of this 2-day workshop was to formulate speciﬁc
and translatable recommendations that would be broadly
applicable across different organs, diseases, and disciplines.
Future endeavors and targeted initiatives aimed at tackling
speciﬁc problems in greater detail are warranted. In this regard,
in addition to supporting interdisciplinary research through
team science grants, (P01, RC2, R24 etc), database resources
for –omics research, human tissue resources, and conference
grant support (U13 and R13), the National Institutes of Health
is currently considering or has started initiatives targeting
small vessels, for example: M2OVE Alzheimer’s disease (AD)
(https://www.nih.gov/news-events/news-releases/decoding-
molecular-ties-between-vascular-disease-alzheimers); Small
Vessel Contributions to Cognitive Impairment and Dementia
(VCID) Biomarkers Consortium: Coordinating Center (RFA-NS-
16-019); Small Vessel Contributions to Cognitive Impairment
and Dementia (VCID) Biomarkers Development Projects (RFA-
NS-16-020); and Mechanistic basis of diffuse white matter
disease in vascular contributions to cognitive impairment and
dementia (RFA-NS-16-021), which were informed by this
workshop and other relevant planning efforts.72–74
Appendix
Workshop participants (in alphabetical order): Dritan Agalliu,
PhD, Columbia University Medical Center; William Aird, MDH,
Harvard University; David A. Antonetti, PhD, University of
Michigan; Manfred Boehm, MD, National Heart, Lung and
Blood Institute, National Institutes of Health (NIH); Claudette
E. Brooks, MD, Ofﬁce of Research on Women’s Health,
National Institutes of Health (NIH); Kathleen M. Caron, PhD,
University of North Carolina at Chapel Hill; William Chilian,
PhD, Northeast Ohio Medical University; Mat J. Daemen, MD,
PhD, University of Amsterdam’s Faculty of Medicine; Robert
D’Amato, MD, PhD, Harvard University; Thomas P. Davis, PhD,
University of Arizona College of Medicine; Adviye Ergul, MD,
PhD, Georgia Regents University; James E. Faber, PhD,
University of North Carolina at Chapel Hill; Ariel R. Gomez,
MD, University of Virginia; Peter Grayson, MD, MSc, National
Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health (NIH); Isabella Grumbach, MD,
PhD, Iowa City VA Medical Center; Jaime Grutzendler, MD,
Yale University; Chenghua Gu, PhD, Harvard University; David
Gutterman, MD, Medical College of Wisconsin; John Hallen-
beck, MD, National Institute of Neurological Disorders and
Stroke, National Institutes of Health (NIH); Ira Herman, PhD,
Tufts University; Jay Humphrey, PhD, Yale University;
Costantino Iadecola, MD, Cornell University; Edward W.
Inscho, PhD, University of Alabama at Birmingham; David
Kleinfeld, PhD, University of California, San Diego; Eng H. Lo,
PhD, Harvard University; Jose A. Lopez, MD, Puget Sound
Blood Center, Seattle; Stephen Macknik, PhD, St. Joseph’s
Hospital and Medical Center, Arizona; Asrar Malik, PhD,
University of Illinois at Chicago; Tanya N. Mayadas, PhD,
Harvard University; Dorian McGavern, PhD, National Institute
of Neurological Disorders and Stroke, National Institutes of
Health (NIH); Gerald A. Meininger, PhD, University of Missouri;
Virginia M. Miller, PhD, Mayo Clinic; Maiken Nedergaard, MD,
PhD, University of Rochester; Mark T. Nelson, PhD, University
of Vermont; Shayn Peirce-Cottler, PhD, National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National
Institutes of Health (NIH); Ipolia Ramadan, PhD, National
Institute of Neurological Disorders and Stroke, National
Institutes of Health (NIH); Gary A. Rosenberg, MD, University
DOI: 10.1161/JAHA.116.004389 Journal of the American Heart Association 10
Small Blood Vessels: Big Health Problems? Bosetti et al
S
P
E
C
IA
L
R
E
P
O
R
T
of New Mexico Health Sciences Center; Ernesto L. Schiffrin,
MD, PhD, McGill University; Peter Searson, PhD, Johns
Hopkins University; Nina Stachenfeld, PhD, Yale University;
Radu V. Stan, MD, PhD, Dartmouth College; Yajaira Suarez,
PhD, Yale University; Eroboghene E. Ubogu, MD, University of
Alabama at Birmingham; Zinaida S. Vexler, PhD, University of
California, San Francisco; Cornelia M. Weyand, MD, PhD,
Stanford University; Berislav V. Zlokovic, MD, PhD, University
of Southern California.
Acknowledgments
The workshop was supported by National Institute of Neurological
Disorders and Stroke, National Heart, Lung and Blood Institute,
National Eye Institute, National Institutes of Health Ofﬁce of Disease
Prevention, and Ofﬁce of Research on Women’s Health. The
Microcirculatory Society sponsored 6 Travel Awards to support the
attendance of trainees and junior faculty members.
Disclosures
Hatsukami: research grant from Philips Healthcare; Bosetti,
Bynoe, Maric-Bilkan, Charette, Cipolla, del Zoppo, Galis, Gould,
Jones, Koenig, Lutty, Stevens, Tolunay, Koroshetz: None.
References
1. Bergers G, Song S. The role of pericytes in blood-vessel formation and
maintenance. Neuro Oncol. 2005;7:452–464.
2. Hill RA, Tong L, Yuan P, Murikinati S, Gupta S, Grutzendler J. Regional blood ﬂow
in the normal and ischemic brain is controlled by arteriolar smooth muscle cell
contractility and not by capillary pericytes. Neuron. 2015;87:95–110.
3. Ghitescu L, Galis Z, Simionescu M, Simionescu N. Differentiated uptake and
transcytosis of albumin in successive vascular segments. Submicrosc Cytol
Pathol. 1988;20:657–669.
4. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober
JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA,
Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophys-
iology of vascular disorders. Blood. 1998;91:3527–3561.
5. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function,
and mechanisms. Circ Res. 2007;100:158–173.
6. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative
vascular beds. Circ Res. 2007;100:174–190.
7. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9
is required for adequate angiogenic revascularization of ischemic tissues:
potential role in capillary branching. Circ Res. 2004;94:262–268.
8. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ,
Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind
LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D,
Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R.
Steps toward mapping the human vasculature by phage display. Nat Med.
2002;8:121–127.
9. Lapi D, Colantuoni A. Remodeling of cerebral microcirculation after ischemia-
reperfusion. J Vasc Res. 2015;52:22–31.
10. Wang S, Zhang H, Dai X, Sealock R, Faber JE. Genetic architecture underlying
variation in extent and remodeling of the collateral circulation. Circ Res.
2010;107:558–568.
11. Limbourg A, Korff T, Napp LC, Schaper W, Drexler H, Limbourg FP. Evaluation
of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb
ischemia. Nat Protoc. 2009;4:1737–1746.
12. Sealock R, Zhang H, Lucitti JL, Moore SM, Faber JE. Congenic ﬁne-mapping
identiﬁes amajor causal locus for variation in the native collateral circulation and
ischemic injury in brain and lower extremity. Circ Res. 2014;114:660–671.
13. Mokin M, Rojas H, Levy EI. Randomized trials of endovascular therapy for
stroke–impact on stroke care. Nat Rev Neurol. 2016;12:86–94.
14. Liu F, McCullough LD. Interactions between age, sex and hormones in
experimental ischemic stroke. Neurochem Int. 2012;61:1255–1265.
15. Traylor M, Rutten-Jacobs LC, Thijs V, Holliday EG, Levi C, Bevan S, Malik R,
Boncoraglio G, Sudlow C, Rothwell PM, Dichgans M, Markus HS. Genetic
associations with white matter hyperintensities confer risk of lacunar stroke.
Stroke. 2016;47:1174–1179.
16. Bodnar RJ, Rodgers ME, Chen WC, Wells A. Pericyte regulation of vascular
remodeling through the CXC receptor 3. Arterioscler Thromb Vasc Biol.
2013;33:2818–2829.
17. Lam CK, Yoo T, Hiner B, Liu Z, Grutzendler J. Embolus extravasation is an
alternative mechanism for cerebral microvascular recanalization. Nature.
2010;465:478–482.
18. Grutzendler J, Murikinati S, Hiner B, Ji L, Lam CK, Yoo T, Gupta S, Haﬂer BP,
Adelman RA, Yuan P, Rodriguez G. Angiophagy prevents early embolus
washout but recanalizes microvessels through embolus extravasation. Sci
Transl Med. 2014;6:226ra31.
19. del Zoppo G, Hawkins B. Throwing out the thromboemboli. N Engl J Med.
2010;363:1282–1284.
20. Miller VM. Sex-based differences in vascular function. Womens Health (Lond
Engl). 2010;6:737–752.
21. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications.
Pharmacol Rev. 2008;60:210–241.
22. Gottesman RF, Schneider AL, Zhou Y, Chen X, Green E, Gupta N, Knopman DS,
Mintz A, Rahmim A, Sharrett AR, Wagenknecht LE, Wong DF, Mosley TH Jr. The
ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex,
and APOE. Neurology. 2016;87:473–480.
23. Bucholz EM, Strait KM, Dreyer RP, Lindau ST, D’Onofrio G, Geda M, Spatz ES,
Beltrame JF, Lichtman JH, Lorenze NP, Bueno H, Krumholz HM. Sex differences
in young patients with acute myocardial infarction: a VIRGO study analysis. Eur
Heart J Acute Cardiovasc Care. 2016;pii:2048872616661847.
24. Hecking M, Bieber BA, Ethier J, Kautzky-Willer A, Sunder-Plassmann G,
S€aemann MD, Ramirez SP, Gillespie BW, Pisoni RL, Robinson BM, Port FK.
Sex-speciﬁc differences in hemodialysis prevalence and practices and the
male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns
Study (DOPPS). PLoS Med. 2014;11:e1001750. doi: 10.1371/journal.pmed.
1001750.
25. Miller VM, Mulvagh SL. Sex steroids and endothelial function: translating basic
science to clinical practice. Trends Pharmacol Sci. 2007;28:263–270.
26. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844–866.
27. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia.
Hypertension. 2013;62:810–817.
28. Knecht S, Wersching H, Lohmann H, Bruchmann M, Duning T, Dziewas R,
Berger K, Ringelstein EB. High-normal blood pressure is associated with poor
cognitive performance. Hypertension. 2008;51:663–668.
29. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell
Metab. 2008;7:476–484.
30. Cipolla MJ. Cerebrovascular function in pregnancy and eclampsia. Hyperten-
sion. 2007;50:14–24.
31. Poston L. Endothelial dysfunction in preeclampsia. Pharmacol Res. 2006;58
(Suppl):69–74.
32. Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and
atherogenesis. Nat Rev Mol Cell Biol. 2009;10:53–62.
33. van Horssen P, van Lier MG, van den Wijngaard JP, VanBavel E, Hoefer IE,
Spaan JA, Siebes M. Inﬂuence of segmented vessel size due to limited imaging
resolution on coronary hyperemic ﬂow prediction from arterial crown volume.
Am J Physiol Heart Circ Physiol. 2016;310:H839–H846.
34. Zhang H, Faber JE. De-novo collateral formation following acute myocardial
infarction: dependence on CCR2⁺ bone marrow cells. J Mol Cell Cardiol.
2015;87:4–16.
35. Geevarghese A, Herman IM. Pericyte-endothelial crosstalk: implications and
opportunities for advanced cellular therapies. Transl Res. 2014;2014
(163):296–306.
36. Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection
and autoimmunity. Kidney Int. 2014;86:905–914.
37. Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus:
multiple immunological phenotypes in a complex genetic disease. Adv
Immunol. 2006;92:1–69.
38. Stephens NG, Parsons A, Schoﬁeld PM, Kelly F, Cheeseman K, Mitchinson
MJ. Randomised controlled trial of vitamin E in patients with coronary
disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:
781–786.
DOI: 10.1161/JAHA.116.004389 Journal of the American Heart Association 11
Small Blood Vessels: Big Health Problems? Bosetti et al
S
P
E
C
IA
L
R
E
P
O
R
T
39. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation
and cardiovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–160.
40. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant
vitamins for the prevention of cardiovascular disease: meta-analysis of
randomised trials. Lancet. 2003;361:2017–2023.
41. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature:
molecular and cellular mechanisms. Hypertension. 2003;42:1075–1081.
42. Erickson JR, He BJ, Grumbach IM, Anderson ME. CaMKII in the cardiovascular
system: sensing redox states. Physiol Rev. 2011;91:889–915.
43. Lopez JA, Zheng Y. Synthetic microvessels. J Thromb Haemost. 2013;11(Suppl
1):67–74.
44. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, Leybaert L,
Molnar Z, O’Donnell ME, Povlishock JT, Saunders NR, Sharp F, Stanimirovic D,
Watts RJ, Drewes LR. Engaging neuroscience to advance translational research
in brain barrier biology. Nat Rev Neurosci. 2011;12:169–182.
45. Ubogu EE. The molecular and biophysical characterization of the human blood-
nerve barrier: current concepts. J Vasc Res. 2013;50:289–303.
46. Osada T, Gu YH, Kanazawa M, Tsubota Y, Hawkins BT, Spatz M, Milner R, del
Zoppo GJ. Interendothelial claudin-5 expression depends on cerebral endothe-
lial cell-matrix adhesion by b(1)-integrins. J Cereb Blood Flow Metab.
2011;31:1972–1985.
47. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease
systematic review and meta-analysis. Neurobiol Aging. 2009;30:337–352.
48. Ubogu EE. Inﬂammatory neuropathies: pathology, molecular markers and
targets for speciﬁc therapeutic intervention. Acta Neuropathol.
2015;130:445–468.
49. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, Benveniste H. Brain-wide
pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest.
2013;123:1299–1309.
50. Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension:
mechanisms and approach to target organ protection. J Clin Hypertens.
2011;13:244–251.
51. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?)
form of target organ damage in mild essential hypertension. J Hypertens.
2001;19:921–930.
52. Endemann DH, Pu Q, De Ciuceis C, Savoia C, Virdis A, Neves MF, Touyz RM,
Schiffrin EL. Persistent remodeling of resistance arteries in type 2 diabetic
patients on antihypertensive treatment. Hypertension. 2004;43:399–404.
53. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment.
Hypertension. 2012;59:367–374.
54. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD.
Paracrine regulation of the renal microcirculation. Physiol Rev. 1996;76:425–
536.
55. Kinlay S, Fang JC, Hikita H, Ho I, Delagrange DM, Frei B, Suh JH, Gerhard M,
Creager MA, Selwyn AP, Ganz P. Plasma alpha-tocopherol and coronary
endothelium-dependent vasodilator function. Circulation. 1999;100:219–221.
56. Rosenberg GA, Bjerke M, Wallin A. Multimodal markers of inﬂammation in the
subcortical ischemic vascular disease type of vascular cognitive impairment.
Stroke. 2014;45:1531–1538.
57. Lucitti JL, Sealock R, Zhang H, Buckley B, Faber JE. Identiﬁcation of the
causal gene in the Dce1 locus, determinant of collateral extent-1, that is
responsible for variation in collateral extent in the mouse. Stroke.
2016;47:3396–3405.
58. van der Hoeven NW, Hollander MR, Yıldırım C, Jansen MF, Teunissen PF,
Horrevoets AJ, van der Pouw Kraan TC, van Royen N. The emerging role of
galectins in cardiovascular disease. Vascul Pharmacol. 2016;81:31–41.
59. Chesler EJ. Out of the bottleneck: the diversity outcross and collaborative
cross mouse populations in behavioral genetics research. Mamm Genome.
2014;25:3–11.
60. Jiwa NS, Garrard P, Hainsworth AH. Experimental models of vascular dementia
and vascular cognitive impairment: a systematic review. J Neurochem.
2010;115:814–828.
61. Federico A, Di Donato I, Bianchi S, Di Palma C, Taglia I, Dotti MT. Hereditary
cerebral small vessel diseases: a review. J Neurol Sci. 2012;322:25–30.
62. Ergul A, Abdelsaid M, Fouda AY, Fagan SC. Cerebral neovascularization in
diabetes: implications for stroke recovery and beyond. J Cereb Blood Flow
Metab. 2014;34:553–563.
63. De Silva TM, Ketsawatsomkron P, Pelham C, Sigmund CD, Faraci FM. Genetic
interference with peroxisome proliferator-activated receptor c in smooth
muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-
dependent mechanism. Hypertension. 2015;65:345–351.
64. Hood L, Tian Q. Systems approaches to biology and disease enable translational
systems medicine. Genomics Proteomics Bioinformatics. 2012;10:181–185.
65. Wong AD, Searson PC. Live-cell imaging of invasion and intravasation in an
artiﬁcial microvessel platform. Cancer Res. 2014;74:4937–4945.
66. Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE. Biomolecular simulation: a
computational microscope for molecular biology. Annu Rev Biophys.
2012;41:429–452.
67. Humphrey JD, Taylor CA. Intracranial and abdominal aortic aneurysms:
similarities, differences, and need for a new class of computational models.
Annu Rev Biomed Eng. 2008;10:221–246.
68. Niklason LE, Yeh AT, Calle EA, Bai Y, Valentin A, Humphrey JD. Enabling tools
for engineering collagenous tissues integrating bioreactors, intravital imaging,
and biomechanical modeling. Proc Natl Acad Sci USA. 2010;107:3335–3339.
69. Grutzendler J, Murikinati S, Hiner B, Ji L, Lam CK, Yoo T, Gupta S, Haﬂer BP,
Adelman RA, Yuan P, Rodriguez G. Angiophagy prevents early embolus
washout but recanalizes microvessels through embolus extravasation. Sci
Transl Med. 2014;6:226–231.
70. Harb R, Whiteus C, Freitas C, Grutzendler J. In vivo imaging of cerebral
microvascular plasticity from birth to death. J Cereb Blood Flow Metab.
2013;33:146–156.
71. Guo S, Zhou Y, Xing C, Lok J, Som AT, Ning M, Ji X, Lo EH. The vasculome of
the mouse brain. PLoS ONE. 2012;7:e52665.
72. Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM,
Greenberg SM, Hutton ML, Knopman DS, Kuzmichev AN, Manly JJ, Marder KS,
Miller BL, Phelps CH, Seeley WW, Sieber BA, Silverberg NB, Sutherland M,
Torborg CL, Waddy SP, Zlokovic BV, Corriveau RA; ADRD 2013 Conference
Organizing Committee. Recommendations of the Alzheimer’s disease-related
dementias conference. Neurology. 2014;83:851–860.
73. Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, Lamb
BT, Montine TJ, Nedergaard M, Schaffer CB, Schneider JA, Wellington C,
Wilcock DM, Zipfel GJ, Zlokovic B, Bain LJ, Bosetti F, Galis ZS, Koroshetz W,
Carrillo MC. Vascular contributions to cognitive impairment and dementia
including Alzheimer’s disease. Alzheimers Dement. 2015;11:710–717.
74. Corriveau RA, Bosetti F, Emr M, Gladman JT, Koenig JI, Moy CS, Pahigiannis K,
Waddy SP, Koroshetz W. The science of vascular contributions to cognitive
impairment and dementia (VCID): a framework for advancing research
priorities in the cerebrovascular biology of cognitive decline. Cell Mol
Neurobiol. 2016;36:281–288.
Key Words: endothelium • hypertension • imaging • ische-
mia • microcirculation • remodeling
DOI: 10.1161/JAHA.116.004389 Journal of the American Heart Association 12
Small Blood Vessels: Big Health Problems? Bosetti et al
S
P
E
C
IA
L
R
E
P
O
R
T
